Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

imsidolimab

A humanized monoclonal antibody directed against the interleukin-36 receptor (IL-36R), with potential anti-inflammatory and immunomodulatory activities. Upon administration, imsidolimab targets, binds to and prevents the activity of IL-36R by the pro-inflammatory cytokine IL-36. This prevents IL-36/IL-36R-mediated signaling pathways. This may inhibit skin inflammation in which the IL-36/IL-36R plays a key role. IL-36 is highly upregulated in certain skin inflammatory conditions.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:ANB019
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search